NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
2027-2028 Officer Nominations Open
We’re looking for individuals interested in serving on the National Lipid Association Board of Directors and the NLA’s five regional chapters. NLA members who are…
LDL-C Monitoring & Measurement Returns to CMS MIPS Quality Payment Program
Today, the United States Centers for Medicare & Medicaid Services (CMS) published the Calendar Year 2027 Physician Fee Schedule Final Rule which finalizes inclusion of…
National Lipid Association Honored with National Forum’s 2026 Public Policy Award
The National Lipid Association (NLA) has been awarded the prestigious Public Policy Award by the National Forum for Heart Disease & Stroke Prevention during its…
Top Line Results from the Phase 3 Lp(a)HORIZON Trial
On September 4, 2026, Novartis announced the topline results of its phase 3 Lp(a)HORIZON trial. Novartis shared that while pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the…
Make Your Voice Heard: Support LDL-C Quality Measurement in the CMS CY 2027 Physician Fee Schedule
The Centers for Medicare & Medicaid Services (CMS) is accepting public comments on the Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule, and…
National Lipid Association Highlights New Meta-Analysis Supporting LDL-C Lowering in Primary Prevention
The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse…
Dietary Patterns & Nutrition Interventions for Individuals with Dyslipidemia
The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.” The NLA leadership…
US Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their…